Introduction
macroscopically normal. However, their lymphatic vessel lumens are constitutively distended compared with the irregularly shaped, collapsed lumens of lymphatic vessels often found in wild-type mice (Huang et al., 2006) . The alteration in the shape of lymphatic vessel lumens is most prominent in the liver and intestine (Huang et al., 2006) . High molecular weight FITC-dextran (average MW 2,000,000) injected subcutaneously in the tail of Crsbp1 -/-mice is cleared from the tail more rapidly than in wild-type mice (Huang et al., 2006) . Since high molecular weight FITC-dextran can only be cleared via lymphatic drainage, we reasoned that Crsbp1 -/-mice might have a constitutive increase in the transit of large molecules, fluids and cells from the interstitial space into the lumen of lymphatic capillaries, a process we call interstitiallymphatic transit (Huang et al., 2006) . To further define the role of CRSBP-1 in the regulation of interstitial-lymphatic transit, FITCdextran was co-injected with and without PDGF-BB, a putative physiological CRSBP-1 ligand, into tails of wild-type mice. PDGF-BB enhanced the clearance of FITC-dextran near the injection site (Huang et al., 2006) . Co-injection of HA, a known CRSBP-1 ligand, also enhanced the clearance of FITC-dextran near the injection site. PDGF-BB was more effective than HA in wild-type mice; however, in Crsbp1 -/-mice, neither PDGF-BB nor HA enhanced the clearance of the FITC-dextran (Huang et al., 2006) . These results support our hypothesis that the Crsbp1-null mutation and binding of CRSBP-1 by its cognate ligands cause opening of lymphatic intercellular junctions, resulting in increased interstitiallymphatic transit (Huang et al., 2006) .
To define the molecular mechanism by which CRSBP-1 ligands regulate the function of lymphatic intercellular junctions, we determined the effects of several CRSBP-1 ligands on the structure (morphology) and function (permeability) of intercellular junctions in the monolayers of LECs, including SVEC4-10 cells and primary human dermal LECs (HDLECs). These CRSBP-1 ligands included putative physiological ligands (PDGF-BB, VEGF-A165 and hyaluronic acid) and two specific ligands (PDGF peptide and VEGF peptide, which are synthetic oligopeptides containing the CRS motifs of PDGF-BB and VEGF-A165, respectively and do not interact with PDGFR and VEGFR2) (supplementary material Fig. S1 ). SVEC4-10 cells are SV40-transformed LEC-like cells (supplementary material Fig. S2 ). We also determined the effects of these CRSBP-1 ligands on the function of lymphatic intercellular junctions by measuring the transit of intradermally injected high molecular weight FITC-dextran and -carrageenan-induced edema fluid from the interstitial space into lymphatic vessels in wild-type and Crsbp1-null mice. In this communication, we show that these CRSBP-1 ligands induce disruption of VE-cadherin-mediated intercellular adhesion and opening of intercellular junctions in a manner dependent on PDGFR activity in LEC monolayers (as evidenced by increased permeability) and in lymphatic vessels in wild-type mice (as evidenced by rapid clearance of injected FITCdextran near the injection site and by attenuated -carrageenaninduced edema).
Results

CRSBP-1 ligands induce disruption of VE-cadherinmediated intercellular adhesion
We hypothesized that CRSBP-1 is involved in the formation of overlapping intercellular junctions of lymphatic endothelial cells in lymphatic vessels and that CRSBP-1 ligands induce opening of the lymphatic intercellular junction (Huang et al., 2006) . Baluk and colleagues (Baluk et al., 2007) demonstrated that VE-cadherin is required for maintenance of lymphatic junctional integrity. To test the hypothesis that CRSBP-1 ligands cause opening of lymphatic intercellular junctions by compromising VE-cadherinand -catenin-mediated intercellular adhesion, we analyzed the subcellular localization of VE-cadherin and its associated protein, -catenin, in monolayers of SVEC4-10 cells treated with CRSBP-1 ligands using immunofluorescence confocal microscopy. Without stimulation, VE-cadherin colocalized with -catenin at the plasma membrane (Fig. 1C ). Upon stimulation with 10 M VEGF peptide and 10 M PDGF peptide for 1 hour, VE-cadherin levels diminished at the plasma membrane, presumably because of increased VE-cadherin endocytosis or internalization (Fig. 1E, H vs 1B) . Additionally, -catenin staining became disorganized into a zigzag pattern (Fig. 1D ,G) and there was no colocalization of VEcadherin and -catenin at the plasma membrane (Fig. 1F,I ). It has been shown that the change in -catenin membrane distribution 1232 Journal of Cell Science 124 (8) (J-L) or 100g/ml HA (M-O) for 1 hour. After incubation, cells were fixed with methanol at -20°C for 10 minutes. Cells were stained with anti--catenin antibody (green) (A,D,G,J,M) and anti-VE-cadherin antibody (red) (B,E,H,K,N) and visualized with a confocal microscope. Cells treated with vehicle showed colocalization of VE-cadherin and -catenin on the plasma membrane (as indicated by an arrowhead in C). CRSBP-1 ligand treatment induced disruption of -catenin distribution from a linear pattern to a zigzag pattern in the cell borders as indicated by arrows (F,I,L,O), diminished plasma membrane distribution of VE-cadherin (E,H,K,N) and decreased colocalization of VE-cadherin and -catenin (F,I,L,O). CRSBP-1 ligand stimulation also enlarged gaps between cells (as indicated by asterisk in F,I,L,O). Scale bar: 10m. from a linear pattern to zigzag pattern is associated with disassembly of the VE-cadherin--catenin complex and disruption of VE-cadherin-mediated cell-cell adhesion (Boccellino et al., 2005; Esser et al., 1998) . Furthermore, when compared with cells treated with vehicle only, gaps and slits appeared between endothelial cells treated with CRSBP-1 ligand, which we believe is due to loss of cell-cell adhesion (Fig. 1F,I ). Stimulation with physiological CRSBP-1 ligands (5 nM VEGF-A165 and 100 g/ml HA) also induced decreased plasma membrane distribution of VEcadherin and disorganization of distribution of -catenin in the membrane from a linear pattern to a zigzag pattern (Fig. 1L,O) . VEGF-A165 is a putative physiological CRSBP-1 ligand for LECs that express very little endogenous VEGFR2, which is a specific receptor for VEGF-A165 in blood vascular endothelial cells (Farrara, 2004) . Taken together, these results suggest that CRSBP-1 ligands inhibit VE-cadherin trans interaction (Boccellino et al., 2005; Esser et al., 1998; Vincent et al., 2004) and impair cell-cell adhesion by inducing disassembly of the VE-cadherin--catenin complex at intercellular junctions in SVEC4-10 cells.
The effects of CRSBP-1 ligands on VE-cadherin--catenin intercellular junctions were also determined in HDLECs. HDLECs were stimulated with CRSBP-1 ligands, as described above. Similarly to SVEC4-10 cells, indirect immunofluorescence staining of unstimulated HDLECs using antibodies against VE-cadherin and -catenin revealed colocalization of VE-cadherin and -catenin at the plasma membrane along the cell borders. HDLECs stimulated with CRSBP-1 ligands (10 M PDGF peptide, 10 M VEGF peptide, 5 nM VEGF-A165 and 100 g/ml HA) exhibited disorganization of the membrane distribution of VE-cadherin--catenin at the intercellular junctions from a linear pattern to a zigzag pattern, with a diminished plasma membrane distribution of VE-cadherin and decreased colocalization of VE-cadherin and -catenin (data not shown). PDGF and VEGF peptides induced more disorganization of VE-cadherin and -catenin than was observed with PDGF-BB and HA (data not shown). Additionally, gaps between cells in HDLEC monolayers stimulated with PDGF and VEGF peptides, and VEGF-A165 were increased (data not shown).
Furthermore, the linear and zigzag staining patterns of VEcadherin--catenin were quantified using the method described previously (Vincent et al., 2005) . The VE-cadherin--catenin immunofluorescence staining of cell borders in HDLECs treated with vehicle only exhibited mainly linear patterns. Treatment with PDGF peptide (10 M), VEGF peptide (10 M), VEGF-A165 (5 nM) and HA (100 g/ml) resulted in increased zigzag patterns in the plasma membrane distribution of VE-cadherin--catenin (n10) (20±3%, 27±3%, 17±4% and 11±3%, respectively). PDGF-BB (2 nM) had moderate effects on the staining patterns of VE-cadherin--catenin (6±2% zigzag patterns) compared with those in vehicletreated cells. This is consistent with the concept that PDGF-BB weakly increases opening of VE-cadherin--catenin intercellular junctions in SVEC4-10 cells. This is probably due to the fact that the PDGF-BB (Abcam ab73229) used in these experiments is not the full-length protein and lacks the CRS motif near the C-terminal end of the protein. PDGF-BB is believed to slightly induce opening of intercellular junctions, mainly via interaction with PDGFR.
CRSBP-1 ligands increase permeability in LEC monolayers in a CRSBP-1-dependent manner
As described above, CRSBP-1 ligands induce opening of VEcadherin--catenin intercellular junctions. This finding raises the possibility that CRSBP-1 ligands are capable of stimulating the permeability of LEC monolayers by inducing opening of intercellular junctions. Using a Transwell system, we determined the permeability of SVEC4-10 cell and HDLEC monolayers stimulated with CRSBP-1 ligands by measuring the passage of FITC-dextran (MW ~40,000) from the upper chamber to the lower chamber. Stimulation of SVEC4-10 cells with 10 M VEGF (Fig.  2Aa ) and 10 M PDGF peptide (Fig. 2Ab) significantly increased transit of FITC-dextran across the cell monolayer when compared with results obtained with the vehicle alone. Treating SVEC4-10 cell monolayers with 100 g/ml HA slightly enhanced the transit of FITC-dextran to the lower chamber (Fig. 2Ac) . The same experiment was performed using HDLECs. VEGF peptide also increased permeability in HDLEC monolayers as determined using the Transwell permeability assay (Fig. 2Ad) . These results indicate that specific CRSBP-1 ligands (VEGF and PDGF peptides) are capable of increasing permeability in SVEC4-10 cell and HDLEC monolayers, presumably by inducing opening of VE-cadherin--catenin intercellular junctions.
To test the hypothesis that CRSBP-1 ligands act specifically with CRSBP-1 to exert its biological activity, we performed genespecific downregulation of CRSBP-1 by transfection of SVEC4-10 cells with Crsbp1 siRNA. At 48 hours after siRNA transfection, about 80% of CRSBP-1 protein was downregulated compared with levels in cells transfected with control siRNA (Fig. 2Ba ). SVEC4-10 cells transfected with control siRNA or Crsbp1 siRNA for 48 hours were used for the Transwell permeability assay. Cells transfected with Crsbp1 siRNA exhibited increased transit of FITCdextran from the upper chamber to the lower chamber compared with cells transfected with control siRNA (Fig. 2Bb) , indicating increased permeability in Crsbp1 siRNA-transfected cells. However, cells transfected with control siRNA exhibited increased permeability upon VEGF peptide stimulation (Fig. 2Bc) . Interestingly, the increase in permeability in ligand-stimulated control cells was similar to that observed in cells transfected with Crsbp1 siRNA. In addition, downregulation of CRSBP-1 expression by transfection of cells with Crsbp1 siRNA abolished VEGF-peptide-stimulated permeability of transfected cell monolayers (Fig. 2Bd) . These results suggest that CRSBP-1 is required for mediation of CRSBP-1-ligand-stimulated permeability in SVEC4-10 cell monolayers. These results are consistent with the fact that Crsbp1-null mice exhibit constitutively increased interstitial-lymphatic transit (Huang et al., 2006) . We hypothesize that this results from constitutive opening of intercellular junctions in lymphatic capillary vessels.
CRSBP-1 ligands induce internalization of VE-cadherin and dissociation of -catenin and p120-catenin from VEcadherin As described above, confocal microscopy of intercellular junction proteins (VE-cadherin and -catenin) reveals that CRSBP-1 ligand stimulation results in decreased cell-surface staining of VEcadherin, decreased colocalization of VE-cadherin and -catenin at the plasma membrane and opening of VE-cadherin intercellular junction in LEC monolayers. These results suggest that CRSBP-1 ligands induce internalization of cell-surface VE-cadherin in LECs. To test this possibility, we performed trypsin digestion experiments to determine whether CRSBP-1 ligands can induce internalization of cell-surface VE-cadherin, because internalized cell-surface proteins are resistant to trypsin digestion. Following treatment of SVEC4-10 cells with vehicle only, 10 M PDGF peptide and 10 M VEGF peptide, cells were untreated (for analysis of the total VE-cadherin) or treated with trypsin to remove cell-surface proteins. The lysates of cells untreated and treated with trypsin were subjected to western blot analysis using anti-VE-cadherin antibodies. Lysates of SVEC4-10 cells, which were not subjected to further incubation with trypsin, contained 130 kDa VE-cadherin (Fig. 3A, lane 1) . This represented the total VE-cadherin in the cells. In these cells, a fraction (~30%) of VE-cadherin was estimated to be trypsin resistant, representing intracellular or internalized VE-cadherin (Fig. 3A, lane 2) . This finding suggests that VEcadherin undergoes internalization and recycling without stimulation by exogenous CRSBP-1 ligands. However, treatment with PDGF and VEGF peptides increased the amount of trypsinresistant VE-cadherin to ~80% of the total VE-cadherin (Fig. 3A , lanes 3 and 4 vs lane 1), suggesting that these peptides stimulate internalization of cell-surface VE-cadherin ~2.7-fold. Similar results were also obtained from the experiments measuring trypsin-resistant cell surface (biotinylated) VE-cadherin following treatment of SVEC4-10 cells with VEGF peptide (data not shown).
In blood vascular endothelial cells, internalization of VEcadherin might result from the dissociation of -catenin or p120-catenin from VE-cadherin. To determine the interaction between VE-cadherin and -catenin or p120-catenin in LECs, SVEC4-10 cells were stimulated with vehicle only, 10 M VEGF peptide or 10 M PDGF peptide for 30 minutes. Stimulated cell lysates were subjected to immunoprecipitation using anti-VE-cadherin antibody followed by SDS-PAGE and immunoblot analysis using anti--catenin antibody or anti-p120-catenin antibody. In vehicle-treated cells, VE-cadherin and -catenin or p120-catenin were found to be co-immunoprecipitated (Fig. 3B, lane 1) . Upon stimulation by VEGF and PDGF peptides, there was a decrease in the amount of -catenin (~50%) and p120-catenin (~90%) co-immunoprecipitated with VE-cadherin (Fig. 3B, lanes 2 and 3 vs lane 1) . These results 1234 Journal of Cell Science 124 (8) were plated onto 6.5 mm Transwell (collagencoated, 3m pore PTFE) membrane inserts and grown overnight. Cell monolayers were treated with vehicle only (control) (a-d), 10M VEGF peptide (a,d), 10M PDGF peptide (b) and 100g/ml HA (c). FITC-dextran (MW 40 kDa; 1 mg/ml) was then added to the upper chamber. At each time period (0, 60, 120, 180, 240, 300 and 360 minutes), an aliquot was taken from the lower chamber to measure its fluorescence intensity (A.U.). *P<0.05 compared with vehicle-only control. (B)Downregulation of CRSBP-1 expression by transfection with Crsbp1 siRNA abolishes CRSBP-1-ligandstimulated permeability in SVEC4-10 cells. Cells were transfected with control or Crsbp1 siRNA for 48 hours. Following transfection, the amounts of CRSBP-1 protein and -actin (as a loading control) were determined by western blot (a). SVEC4-10 cells (1.5ϫ10 5 ) transfected with control or Crsbp1 siRNA were plated onto 6.5 mm Transwell (collagen-coated, 3m pore PTFE) membrane inserts and grown overnight. Cell monolayers were treated with vehicle only or 10M VEGF peptide. FITC-dextran (MW 40 kDa; 1 mg/ml) was then added to the upper chamber. At each time point, an aliquot was taken from the lower chamber to measure its fluorescence intensity (A.U.). Monolayers of cells transfected with Crsbp1 siRNA exhibited greater permeability than monolayers of cells transfected with control siRNA (b). Monolayers of cells transfected with control siRNA showed VEGF-peptide-increased permeability of the cell monolayer (c), whereas in monolayers of cells transfected with Crsbp1 siRNA, VEGFpeptide-increased permeability of the cell monolayer was abolished (d). *P<0.05, compared with control siRNA or vehicle-only control.
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indicate that specific CRSBP-1 ligands are capable of increasing dissociation of -catenin and p120-catenin from VE-cadherin.
CRSBP-1 forms complexes with PDGFR and -catenin
CRSBP-1 is known to form complexes with PDGFR in SSVtransformed cells (Huang et al., 2006) . We determined whether this complex formation also occurs in SVEC4-10 cells by immunoprecipitation with rabbit anti-CRSBP-1 serum or nonimmune serum followed by immunoblot analysis with rabbit anti-PDGFR serum. PDGFR was present in the immunoprecipitates using anti-CRSBP-1 serum (Fig. 3C , lane 2) but not non-immune serum (Fig. 3C, lane 1) . Interestingly, ~10% of the total PDGFR was found to form complexes with CRSBP-1 (Fig. 3C , lane 2 vs lane 3). Because CRSBP-1 ligands stimulate dissociation of -catenin from VE-cadherin, we hypothesized that the CRSBP-1-PDGFR complex interacts with VE-cadherin or -catenin in the absence of CRSBP-1 ligands. To test this hypothesis, SVEC4-10 cell lysates were immunoprecipitated using pre-immune serum, anti-CRSBP-1 serum or anti-PDGFR serum, followed by immunoblot analysis with anti--catenin antibody or anti-VEcadherin antibody. The immunoprecipitates using anti-CRSBP-1 serum (Fig. 3D , lane 2) or anti-PDGFR serum (Fig. 3D , lane 4) contained -catenin but not VE-cadherin (data not shown). These results suggest that CRSBP-1 forms complexes with PDGFR and -catenin and that the CRSBP-1-PDGFR complex might associate with -catenin to form ternary complexes. These results also suggest that PDGFR is involved in mediating CRSBP-1-ligandinduced disassembly and opening of VE-cadherin--catenin intercellular junctions.
CRSBP-1 ligands stimulate tyrosine phosphorylation of PDGFR
As described above, CRSBP-1 forms complexes with PDGFR and -catenin in SVEC4-10 cells. It is possible that CRSBP-1 ligands induce disruption of VE-cadherin-and -catenin-mediated intercellular adhesion by stimulating the protein tyrosine kinase activity of PDGFR in the CRSBP-1-PDGFR complex and subsequent tyrosine phosphorylation of VE-cadherin and -catenin (probably by stimulated PDGFR). It has recently been reported that VEGF-A stimulates serine phosphorylation of VE-cadherin, resulting in disruption of intercellular adhesion and opening of intercellular junctions in blood vascular endothelial cells (Gavard and Gutkind, 2006) . To test a similar possibility, we determined the levels of tyrosine phosphorylation of several protein species in SVEC4-10 cells stimulated with 10 M VEGF peptide or vehicle only using western blot analysis with anti-phosphotyrosine antibody. Upon VEGF peptide stimulation, there was a remarkable increase in tyrosine phosphorylation of a protein at ~180 kDa, which coincides with the molecular mass of PDGFR (Hellberg et al., 2010) . Based on this preliminary result and the finding of the complex formation of CRSBP-1 and PDGFR in SVEC4-10 cells and other cell types expressing both CRSBP-1 and PDGFR (Boensch et al., 1999) , we hypothesized that CRSBP-1 ligands can stimulate tyrosine phosphorylation of PDGFR by activation of PDGFR in the CRSBP-1-PDGFR complex. To test this hypothesis, we determined the level of tyrosine phosphorylation of PDGFR by immunoprecipitation with anti-PDGFR serum, followed by immunoblotting for phosphotyrosine in SVEC4-10 cells stimulated by PDGF peptide, VEGF peptide, VEGF-A165 or PDGF-BB. CRSBP-1 ligands, including 10 M PDGF peptide, 10 M VEGF peptide, 5 nM VEGF-A165 and 5 nM PDGF-BB all stimulated tyrosine phosphorylation of PDGFR after 30 minutes of stimulation in SVEC4-10 cells (Fig. 4A , lanes 2-5, respectively). By contrast, in NIH3T3 cells, which are fibroblasts that express a very low level of endogenous CRSBP-1 but a high level of endogenous PDGFR, 10 M concentrations of these CRSBP-1 ligands did not significantly stimulate tyrosine phosphorylation of PDGFR (Fig. 4B, lanes 2 and 3) . However, PDGF-BB is a potent 1235 CRSBP-1 regulates intercellular junctions and trypsinuntreated and trypsin-treated cell lysates were then analyzed by western blot analysis using anti-VE-cadherin antibody. PDGF peptide and VEGF peptide enhanced internalization of VE-cadherin ~2.7 fold (~80% of the total VEcadherin; lanes 3 and 4) when compared with that observed in cells simulated with vehicle only (~30% of the total VE-cadherin (lane 2). (B)SVEC4-10 cells were treated with vehicle only (control) (lane 1), 10M VEGF peptide (lane 2) or 10M PDGF peptide (lane 3) for 30 minutes. Cell lysates were immunoprecipitated using anti-VE-cadherin antibody. Immunoprecipitated proteins were subjected to SDS-PAGE followed by quantitative western blot analysis using anti--catenin and anti-p120-catenin antibodies. VEGF peptide and PDGF peptide induced dissociation of -catenin and p120-catenin from VE-cadherin (lanes 2 and 3, respectively). (C,D)CRSBP-1 forms complexes with PDGFR and -catenin in the absence of exogenous CRSBP-1 ligands. Cell lysates of SVEC4-10 cells were immunoprecipitated using nonimmunized rabbit serum (NRS) (C,D, lane 1), anti-CRSBP-1 serum (C,D, lane 2) or anti-PDGFR serum (C, D, lanes 3 and 4, respectively). Immunoprecipitated proteins were resolved by SDS-PAGE, followed by western blot analysis using anti-PDGFR serum (C) or anti--catenin antibody (D). Anti-CRSBP-1 serum immunoprecipitated PDGFR (C, lane 2), which was ~10% of the total PDGFR (C, lane 2 vs lane 3). -catenin was present in the immunoprecipitates using anti-CRSBP-1 serum and anti-PDGFR serum (D, lanes 2 and 4, respectively), and in the cell lysates (D, lane 3). Arrowheads indicate the protein band that corresponds to PDGFR (180 kDa) or -catenin (90 kDa). The bar indicates the location of a protein that might be a proteolytic product of PDGFR (C, lanes 2 and 3). The three high molecular weight species might be post-translationally modified products of -catenin, which were immunoprecipitated and concentrated by anti-CRSBP-1 antibody (D, lanes 2 and 4).
stimulator of tyrosine phosphorylation of PDGFR in both cell types (Fig. 4A , lane 5 and Fig. 4B, lane 4) . PDGF-BB-stimulated tyrosine phosphorylation of PDGFR was ~tenfold greater than that stimulated by PDGF peptide or VEGF peptide (Fig. 4A , lane 5 vs lanes 2 and 3). These results are consistent with the observation that only ~10% of the total PDGFR forms complexes with CRSBP-1. CRSBP-1 ligands appear to stimulate PDGFR in the CRSBP-1-PDGFR complex.
Because VEGF and PDGF peptides are rich in basic amino acid residues, we determined whether poly-L-lysine is also capable of activating PDGFR. SVEC4-10 cells were treated with 10 M VEGF peptide, 10 M PDGF peptide or 20 M poly-L-lysine (average molecular mass ~40 kDa) for 30 minutes and the level of tyrosine phosphorylation in PDGFR was determined as described above. Poly-L-lysine was only capable of slightly increasing tyrosine phosphorylation of PDGFR when compared with vehicleonly treatment in SVEC4-10 cells (Fig. 4C, lanes 1 and 4) . CRScontaining peptides (PDGF peptide and VEGF peptide; Fig. 4C , lanes 2 and 3, respectively), which contain a cluster of basic amino acid residues (Boensch et al., 1995) , elicited a stronger effect on 1236 Journal of Cell Science 124 (8) PDGFR tyrosine phosphorylation than poly-L-lysine did (Fig.  4C, lane 4) . This suggests that certain amino acid sequences in the CRS motifs, which are rich in basic amino acid residues, are required for the optimal activity of CRSBP-1 ligands. The doseresponse relationship of CRSBP-1-ligand-stimulated tyrosine phosphorylation of PDGFR was further dissected by treating SVEC4-10 cells with VEGF peptide and PDGF peptide at 0, 0.1, 2, 10, 20 M (Fig. 4D ). VEGF peptide (Fig. 4Da ) and PDGF peptide (Fig. 4Db ) stimulated tyrosine phosphorylation in a dosedependent manner with EC 50 values of ~2 M.
To determine whether CRSBP-1 ligands stimulate and activate PDGFR, SVEC4-10 cells were pretreated with the specific PDGFR kinase inhibitor Tyrphostin AG 1296 (Kovalenko et al., 1997) before they were stimulated with CRSBP-1 ligands. Pretreatment of cells with 1 M Tyrphostin abolished PDGF and VEGF peptide-stimulated tyrosine phosphorylation of PDGFR (Fig. 4E , lanes 5 and 6 vs lanes 2 and 3). These results indicate that this specific PDGFR kinase inhibitor abolishes CRSBP-1-ligandstimulated tyrosine phosphorylation and activation of PDGFR. These results also suggest that CRSBP-1 ligands probably stimulate activation and tyrosine phosphorylation (most likely autophosphorylation) of PDGFR through interaction with CRSBP-1 in the CRSBP-1-PDGFR complex. This explanation is supported by other observations: (1) CRSBP-1 ligands fail to stimulate tyrosine phosphorylation of PDGFR in cells expressing very low levels of CRSBP-1 (e.g. NIH3T3 cells), and (2) specific CRSBP-1 ligands stimulate tyrosine phosphorylation of PDGFR 10% as efficiently as PDGF-BB in SVEC4-10 cells. In these cells, ~10% of the total PDGFR form complexes with CRSBP-1 as determined by immunoprecipitation and immunoblot analysis.
CRSBP-1 ligands stimulate tyrosine phosphorylation of VE-cadherin and -catenin
The adhesive state of the VE-cadherin--catenin intercellular junction can be regulated via tyrosine phosphorylation of VEcadherin and -catenin (Piedra et al., 2003; Potter et al., 2005) . In SVEC4-10 cells and HDLECs stimulated with or without CRSBP-1 ligands, we determined the levels of tyrosine phosphorylation of VE-cadherin and -catenin by western blot analysis and indirect immunofluorescence staining using tyrosine-phosphorylation-sitespecific anti-VE-cadherin and anti--catenin antibodies. In SVEC4-10 cells, specific CRSBP-1 ligands (VEGF peptide and PDGF peptide) and putative physiological CRSBP-1 ligands (VEGF-A165 and PDGF-BB) stimulated tyrosine phosphorylation of VEcadherin at Tyr658 and Tyr731 ~two-to threefold (Fig. 4F , lanes 2-5) more efficiently than the control vehicle treatment (Fig. 4F , lane 1). These CRSBP-1 ligands stimulated tyrosine phosphorylation of -catenin at Tyr142 ~1.6-fold. In HDLECs, the same CRSBP-1 ligands also stimulated tyrosine phosphorylation of VE-cadherin at Tyr658 and Tyr731 ~two-to threefold (Fig. 4G , lanes 2-5) more efficiently than the control vehicle treatment (Fig.  4G, lane 1) . The other CRSBP-1 ligand HA at 100 g/ml only slightly stimulated tyrosine phosphorylation of VE-cadherin at Tyr731, but had no effect on tyrosine phosphorylation of VEcadherin at Tyr658 (Fig. 4G , lane 6). CRSBP-1 ligands (VEGF peptide, PDGF peptide, VEGF-A165 and PDGF-BB) stimulated tyrosine phosphorylation of -catenin at Tyr142 by ~1.4-fold (Fig.  4G , lanes 2-5), whereas HA stimulation had no effect on -catenin tyrosine phosphorylation (Fig. 4G, lane 6) . The effects of CRSBP-1 ligands on tyrosine phosphorylation of VE-cadherin and -catenin were also determined with indirect immunofluorescence 1237 CRSBP-1 regulates intercellular junctions lanes 1 and 4) , 10M PDGF peptide (lanes 2 and 5) or 10M VEGF peptide (lanes 3 and 6). Cell lysates were immunoprecipitated using anti-PDGFR serum followed by immunoblot analysis using anti-phosphotyrosine antibody. PDGF peptide and VEGF peptide stimulated tyrosine phosphorylation of PDGFR (lanes 2 and 3, respectively). Pretreatment with Tyrphostin abolished the peptide-stimulated tyrosine phosphorylation of PDGFR (lanes 5 and 6). (F,G)CRSBP-1 ligands stimulate tyrosine phosphorylation of VE-cadherin and -catenin in SVEC4-10 cells and HDLECs. SVEC4-10 cells (F) and HDLECs (G) were treated with vehicle only (control) (lane 1), 10M VEGF peptide (lane 2), 10M PDGF peptide (lane 3), 5 nM VEGF-A165 (lane 4), 2 nM PDGF-BB (lane 5), and 150g/ml HA (F, lane 6) for 30 minutes. Cell lysates were subjected to SDS-PAGE, followed by western blot analysis using anti-VE-cadherin PY658, anti-VE-cadherin PY731, and anti--catenin PY142 antibodies. The membranes were also blotted using anti-VEcadherin and anti--catenin antibodies as loading controls. CRS-containing peptides (VEGF peptide and PDGF peptide) and proteins (VEGF-A165 and PDGF-BB) stimulated tyrosine phosphorylation of VE-cadherin at Tyr658 and Tyr731, and of -catenin at Tyr142 in both cell types (F,G, lanes 2-5). HA stimulation in HDLECs slightly increased the tyrosine phosphorylation of VE-cadherin at Tyr731 but had no effect on tyrosine phosphorylation of VE-cadherin at Tyr658 and of -catenin at Tyr142 (G, lane 6). (H)VEGF peptide stimulates tyrosine phosphorylation of VE-cadherin and -catenin at intercellular junctions in SVEC4-10 cells.
Cells were stimulated with vehicle only or 10M VEGF peptide for 30 minutes. Stimulated cells were fixed and stained with anti-VE-cadherin PY658, anti-VEcadherin PY731, and anti--catenin PY142 antibodies, followed by FITC-conjugated goat anti-rabbit IgG and visualized with a fluorescence microscope. VEGF peptide stimulation increased tyrosine phosphorylation of VE-cadherin at Tyr-658 and Tyr731 (b and d) compared with vehicle alone (a and c). VEGF peptide also stimulated tyrosine phosphorylation of -catenin at Tyr142 (f) when compared with vehicle alone (e). The arrow indicates the discontinuous punctuate distribution of tyrosine-phosphorylated VE-cadherin and -catenin at the plasma membrane (b, d and f). Scale bar: 10m. staining using tyrosine-phosphorylation-site-specific antibodies to VE-cadherin and -catenin. In SVEC4-10 cells, VEGF peptide stimulation increased the localization of tyrosine-phosphorylated VE-cadherin and -catenin at the plasma membrane in a discontinuous punctate distribution (Fig. 4Hb,d,f vs 4Ha,c,e) . These results indicate that CRSBP-1 ligands (PDGF peptide, VEGF peptide, PDGF-BB and VEGF-A165) stimulate tyrosine phosphorylation of VE-cadherin and -catenin in SVEC4-10 cells, whereas HA, which is also a CRSBP-1 ligand, only stimulates limited tyrosine phosphorylation of VE-cadherin and does not affect -catenin tyrosine phosphorylation in these cells. Similar results were also obtained when HDLECs were used for the same set of experiments (data not shown). Because phosphorylation of intercellular junction proteins VE-cadherin and -catenin has a pivotal role in regulation of permeability in endothelial cell monolayers (Boccellino et al., 2005; Esser et al., 1998; Gavard and Gutkind, 2006; Piedra et al., 2003; Potter et al., 2005; Vincent et al., 2004) , these results might explain why HA is weaker than other CRSBP-1 ligands in stimulating permeability in LEC monolayers and interstitial-lymphatic transit in mice (Huang et al., 2006) .
PDGFR mediates CRSBP-1-ligand-stimulated tyrosine phosphorylation of VE-cadherin
To determine whether PDGFR is involved in CRSBP-1-ligandstimulated tyrosine phosphorylation of VE-cadherin, we determined the effects of CRSBP-1 ligands on tyrosine phosphorylation of VE-cadherin in SVEC4-10 cells pretreated with and without Tyrphostin using SDS-PAGE and western blot analysis. SVEC4-10 cells were pretreated with or without 1 M Tyrphostin for 30 minutes and then treated with vehicle only, 10 M VEGF peptide, 10 M PDGF peptide or 100 g/ml HA. PDGF peptide (Fig. 5A , lane 2) and VEGF peptide (Fig. 5A, lane 3) stimulated phosphorylation of VE-cadherin at Tyr658 and Tyr731 ~1.6-fold and ~2.5-fold, respectively, when compared with vehicle-only treatment, whereas HA stimulated phosphorylation of VE-cadherin at only Tyr731 (Fig. 5A, lane 4) . Pretreatment of SVEC4-10 cells with Tyrphostin abolished CRSBP-1-ligand-stimulated tyrosine phosphorylation of VE-cadherin (Fig. 5A , lanes 6 and 7 vs lanes 2 and 3). Tyrphostin also attenuated ligand-unstimulated tyrosine phosphorylation of VE-cadherin in these cells (Fig. 5A , lane 5 vs lane 1).
PDGFR kinase activity is crucial in CRSBP-1 ligandinduced opening of VE-cadherin--catenin intercellular junctions
As described above, the binding of specific CRSBP-1 ligands to CRSBP-1 triggers the molecular disassembly of VE-cadherin--catenin intercellular junctions and formation of microscopically visible intercellular gaps, leading to increased permeability of LEC monolayers. Because CRSBP-1 ligands stimulate tyrosine phosphorylation and activation of PDGFR, we wished to determine whether PDGFR is the crucial signaling protein that mediates CRSBP-1-ligand-stimulated effects in LECs. SVEC4-10 cell monolayers were pretreated with or without 1 M Tyrphostin, followed by stimulation with vehicle only, 10 M VEGF peptide (Fig. 5B) or 10 M PDGF peptide (data not shown). In vehiclestimulated cells without Tyrphostin pretreatment, VE-cadherin and -catenin colocalized at the plasma membrane and displayed linear patterns in the plasma membrane distribution (Fig. 5Bc) . Stimulation with VEGF peptide (Fig. 5Bd,e,f) and PDGF peptide (data not shown) resulted in decreased plasma membrane 1238 Journal of Cell Science 124 (8)
Fig. 5. Tyrphostin inhibits CRSBP-1-ligand-stimulated tyrosine phosphorylation of VE-cadherin, VEGF-peptide-induced disassembly and opening of VE-cadherin--catenin intercellular junctions in SVEC4-10 cells.
(A)Cells were either pretreated with vehicle only (-AG1296, lanes 1-4) or with 1M Tyrphostin for 1 hour (+AG1296, lanes 5-8). Cells were then treated with vehicle only (control) (lanes 1 and 5), 10M PDGF peptide (lanes 2 and 6), 10M VEGF peptide (lanes 3 and 7) or 100g/ml HA (lanes 4 and 8) for 30 minutes. Cell lysates were subjected to SDS-PAGE analysis followed by immunoblot analysis using anti-VE-cadherin PY658 and anti-VE-cadherin PY731 antibodies. The membranes were also blotted using anti-VE-cadherin as a loading control. CRS-containing peptides (PDGF and VEGF peptides) stimulated tyrosine phosphorylation of VE-cadherin at Tyr658 and Tyr731 (lanes 2 and 3, respectively). HA stimulated phosphorylation of VE-cadherin at Tyr731 but had no effect on phosphorylation of VE-cadherin at Tyr658. Pretreatment with Tyrphostin abolished CRSBP-1-ligand-stimulated tyrosine phosphorylation of VE-cadherin (lanes 6-8). (B)Confluent cells were pretreated with vehicle only (a-c) or 1M Tyrphostin (g-l) for 1 hour. Cells were then stimulated with vehicle only (a-c) or 10M VEGF peptide (d-f) for 1 hour. Cells were fixed and stained with anti-VE-cadherin and anti--catenin antibodies followed by confocal immunofluorescence microscopy. VEGF peptide induced disorganization of -catenin and internalization of VE-cadherin (d-f,j-l). Pretreatment of cells with this PDGFR kinase inhibitor abolished disassembly of VE-cadherin junctions induced by VEGF peptide and microscopically visible gaps between cells (l). Arrowheads (c,i,l) and arrows (f) indicate the localization of the linear and zigzag patterns of -catenin at the plasma membrane, respectively. Asterisk indicates the localization of the gaps between cells (f). Scale bar: 10m. distribution of VE-cadherin and disorganization of -catenin from a linear pattern to a zigzag pattern (Fig. 5Bf vs 5Bc) . However, pretreatment of SVEC4-10 cells with 1 M Tyrphostin abolished VEGF-peptide-induced (Fig. 5Bl vs 5Bf ) and PDGF peptideinduced (data not shown) disorganization (formation of zigzag patterns) of VE-cadherin--catenin intercellular junctions. In the control experiments, pretreatment of SVEC4-10 cells with 1 M Tyrphostin only did not alter the distribution of either VE-cadherin or -catenin when compared with cells without inhibitor pretreatment (Fig. 5Bi vs 5Bc) . These results suggest that Tyrphostin effectively abolishes VEGF-peptide-and PDGF-peptideinduced opening of VE-cadherin--catenin intercellular junctions.
Specific CRSBP-1 ligands stimulate interstitial-lymphatic transit in mice in a CRSBP-1-dependent manner
We previously demonstrated that PDGF-BB and HA increase entry of large molecules from the interstitial space into lymphatic vessels (interstitial-lymphatic transit) in wild-type mice but not Crsbp1 -/-mice (Huang et al., 2006) , as determined by intradermal injection of high molecular weight FITC-dextran in mouse tails and by monitoring the decay in fluorescence intensity near the injection site. The results from these studies indicate that CRSBP-1 mediates PDGF-BB-and HA-induced increase in interstitial-lymphatic transit. However, it is possible that, in addition to CRSBP-1, PDGFR is also involved in PDGF-BB-stimulated interstitiallymphatic transit. To test this possibility, we determined the effect of PDGF peptide, a specific CRSBP-1 ligand which does not bind to PDGFR, on interstitial-lymphatic transit, as determined by using the FITC-dextran tail injection assay (Huang et al., 2006) . PDGF peptide (5 g/20 l) was capable of stimulating interstitiallymphatic transit (Fig. 6Aa) . It appeared to accelerate the egress of FITC-dextran more than PDGF-BB at their optimal concentrations (Fig. 6Ab) . The reason that PDGF peptide is more potent than PDGF-BB is unknown. This might be due to the fact that PDGF-BB used in the experiments is not a full-length protein and lacks the putative CRS motif. PDGF peptide and PDGF-BB might exert their different effects by binding to CRSBP-1 and PDGFR, respectively.
To further define the effects of specific CRSBP-1 ligands on interstitial-lymphatic transit, we used the system of -carrageenaninduced paw edema. The system has been well characterized (Otterness and Moore, 1988; Wise et al., 2007 ). An acute inflammatory response induced by -carrageenan is characterized by an increase in vascular permeability and inflammatory cell infiltration, leading to edema formation, as a result of extravasation of fluid and protein accumulation at the inflammatory site. It can provide a quantitative measurement of alterations in the transit of fluid from the interstitial space into the lumen of lymphatic capillaries. For example, the degree of the attenuation of -carrageenan-induced paw edema corresponds to the magnitude of the opening of intercellular junctions in lymphatic vessels and increased interstitial-lymphatic transit of fluid. Using this assay, Crsbp1 -/-mice exhibited attenuated swelling (or edema) compared with wild-type mice (Fig. 6Ba ). Significant attenuation of paw swelling was observed 1 hour after injection of -carrageenan. A maximal attenuation of ~40% was observed 3 hour after -carrageenan injection (Fig. 6Ba) . This suggests that constitutively increased interstitial-lymphatic transit of fluid results in attenuation of edema in Crsbp1 -/-mice. This result is consistent with the observation of constitutively increased interstitial-lymphatic transit of fluid in Crsbp1 -/-mice as determined using the FITC-dextran tail injection assay (Huang et al., 2006) . Furthermore, specific CRSBP-1 ligands (VEGF peptide and PDGF peptide) attenuated paw swelling by ~30% in wild-type mice (Fig. 6Bb,c) . By contrast, these peptides did not affect -carrageenan-induced swelling in Crsbp1 -/-mice (Fig. 6Bd,e) . The histological analysis of paw edema (Fig. 6C) revealed that PDGF peptide and VEGF peptide effectively reduced fluid accumulation in paw edema lesions in wild-type mice (Fig. 6Cb,c vs 6Ca ), whereas these peptides did not significantly affect -carrageenan-induced paw edema in Crsbp1 -/-mice (Fig. 6Ce,f vs 6Cd ). PDGF peptide, VEGF peptide, HA and VEGF-A165 decreased the paw edema in a dose-dependent manner (Fig. 6Da-d, respectively) . It is important to note that HA was not as potent as PDGF peptide, VEGF peptide and VEGF-A165 in decreasing paw edema at their optimal doses. These results indicate that Crsbp1-null mice and wild-type mice treated with CRSBP-1 ligands exhibit attenuated -carrageenan-induced swelling in mouse paws compared with wild-type mice and wildtype mice treated with vehicle only, respectively and that this attenuation is due to opening of intercellular junctions in lymphatic vessels and increased interstitial-lymphatic transit of fluid in the paw tissues of Crsbp1-null mice and wild-type mice treated with CRSBP-1 ligands. These results also support the contention that Crsbp1-null mutation and CRSBP-1 ligand stimulation can cause opening of intercellular junctions in lymphatic vessels, resulting in increased interstitial-lymphatic transit of fluid.
PDGFR kinase activity is required for CRSBP-1-ligandstimulated interstitial-lymphatic transit
As described above, the PDGFR kinase activity is pivotal in CRSBP-1-ligand-induced opening of lymphatic intercellular junctions. To define the role of the PDGFR kinase activity in CRSBP-1-ligand-stimulated interstitial-lymphatic transit in wildtype mice, we determined the effect of the PDGFR kinase activity inhibition on interstitial-lymphatic transit in mice using the system of -carrageenan-induced mouse paw edema. Hind paws of wildtype mice were injected with 1% -carrageenan and either Tyrphostin or Tyrphostin + VEGF peptide. In this experiment, two additional groups of mice were injected with 1% -carrageenan and 1% -carrageenan + VEGF peptide, as negative and positive controls, respectively. VEGF peptide stimulation was capable of attenuating -carrageenan-induced paw edema compared with vehicle-treated animals (Fig. 6E) . Treatment with Tyrphostin alone enhanced paw edema when compared with the vehicle control; it is likely that this abolished the action of endogenous CRSBP-1 ligands under the experimental conditions. Moreover, treatment with Tyrphostin abolished VEGF-peptide-induced attenuation of paw edema (Fig. 6E) . Together with the results from the cell experiments, these results suggest that inhibition of PDGFR protein kinase activity can effectively abolish CRSBP-1-ligandinduced opening of lymphatic intercellular junctions in lymphatic vessels.
Discussion
Here, we demonstrate that CRSBP-1 forms complexes with PDGFR in LECs. We also demonstrate that pretreatment or coinjection with the PDGFR inhibitor abolishes the CRSBP-1-ligand-induced effects in cultured LECs and in animals. Based on our results and results published by others (Knudsen et al., 1995; Piedra et al., 2003; Potter et al., 2005; Dejana et al., 2008; Hartsock et al., 2008) , we propose a model (Fig. 7) to illustrate the mechanism by which CRSBP-1 ligands induce opening of intercellular adherens junctions in LECs. This model stipulates that, in the unstimulated state, VE-cadherin mediates intercellular adhesion by forming trans homodimers with VE-cadherin from adjacent cells. VE-cadherin-mediated adhesion is maintained through the interaction of the VE-cadherin cytoplasmic tail with -catenin and p120-catenin. These catenin interactions maintain localization of VE-cadherin at the plasma membrane. Furthermore, -catenin couples VE-cadherin to the actin cytoskeleton by interacting with -catenin. Our model proposes that CRSBP-1, a 120 kDa disulfide-linked homodimeric membrane protein that forms complexes with the monomeric form of PDGFR, has an important role in lymphatic vessel biology. Upon ligand binding to CRSBP-1, the PDGFR in the CRSBP-1 complex is induced to form dimers or oligomers, resulting in activation and tyrosine phosphorylation (autophosphorylation) of the PDGFR. Activated PDGFR or PDGFR downstream effectors (cytoplasmic protein tyrosine kinases) (Adam et al., 2010) are responsible for tyrosine phosphorylation of VE-cadherin at Tyr658 and Tyr731 and of -catenin at Tyr142. Tyrosine phosphorylation of VE-cadherin at these residues prevents -catenin and p120-catenin from binding to VE-cadherin. -catenin and p120-catenin then become dissociated from VE-cadherin, resulting in destabilization and internalization of VE-cadherin. Furthermore, tyrosine phosphorylation of -catenin hinders the association of -catenin with -catenin, causing VE-cadherin to uncouple from the actin cytoskeleton. Consequently, VE-cadherin-mediated intercellular adhesion is disrupted, leading to opening of intercellular junctions with resulting modulation of properties of lymphatic vessels (Fig.  7) . This model describes how CRSBP-1 mediates ligand-stimulated interstitial-lymphatic transit through regulation of VE-cadherin intercellular junctions.
The CRSBP-1-mediated regulation of interstitial-lymphatic transit demonstrated here might have an important role in interstitial-lymphatic transit or trafficking of immune and carcinoma cells during immune responses and lymphatic metastasis, respectively. Immune cells such as dendritic cells initiate immune responses after they acquire antigens from the interstitial space and migrate to lymphatic vessels and lymph nodes where they activate naive T-cells. The primary tumor can be spread to other tissues and organs through blood and lymphatic systems (Ji, 2009) . Lymphatic vessels appear to be used often by certain carcinomas such as breast cancer to metastasize to other tissues (Eccles et al., 2007) . These immune and carcinoma cells in the interstitial space might migrate into the lumen of lymphatic vessels by secreting or using CRSBP-1 ligands to open intercellular junctions in lymphatic vessels, which results in increased interstitial-lymphatic transit. The interstitial-lymphatic transit of immune and carcinoma cells has been shown to require physical contact between these cells and lymphatic vessels. These cells are also known to produce CRSBP-1 ligands, such as members of the PDGF superfamily and CRScontaining cytokines (Cao, 2005; Eccles et al., 2007; Robbiani et al., 2000) . The expression levels of PDGF-BB in tumors are correlated with their tendency to produce lymphatic metastasis (Cao, 2005; Cao et al., 2006) . VEGF-C produced by tumors promotes tumor-cell invasion by increasing lymphatic metastasis (He et al., 2005) . Antibodies against CCL19, which contains a typical CRS motif and is a putative CRSBP-1 ligand, block accumulation of dendritic cells in the lymph nodes (Robbiani et al., 2000) .
A well-known mechanism that governs interstitial-lymphatic flow is interstitial fluid (hydrostatic) pressure (IFP) dynamics (Aukland and Reed, 1993) . In blood vascular capillary beds, plasma fluid and protein are filtrated into the interstitial compartment. Increased fluid in the interstitial compartment results in an increased hydrostatic pressure gradient between the interstitial space and the lymphatic capillary lumen. As interstitial fluid volume and hydrostatic pressure increase, the anchoring filaments that connect LECs to the collagen and elastin fibers are stretched, resulting in opening of intercellular junctions and blind ends of lymphatic capillaries as well as distention of lumens of lymphatic capillaries (Leak, 1976; Skobe and Detmar, 2000) . Consequently, increased interstitial fluid enters lymphatic capillaries, thus increasing interstitial-lymphatic transit. This IFP-regulated interstitiallymphatic transit appears to be involved in fluid homeostasis in tissues, but is not likely to be responsible for driving immune and 1241 CRSBP-1 regulates intercellular junctions carcinoma cells into lymphatic vessels during immune responses and lymphatic metastasis. The mechanisms regulating interstitiallymphatic transit other than that regulated by IFP are not yet clear (Aukland and Reed, 1993) . Here, we provide evidence indicating a novel ligand-regulatory mechanism of interstitial-lymphatic transit.
According to the model (Fig. 7) , PDGFR in the CRSBP-1-PDGFR complex has an important role in mediating CRSBP-1-ligand-stimulated permeability in LECs and interstitial-lymphatic transit in whole animals. This model raises several questions, including: (1) is the signaling pathway mediated by the CRSBP-1-PDGFR complex different from that mediated by free PDGFR (which contributes 90% of the total PDGFR in LECs)? (2) If so, are the cellular responses also different? The signaling and cellular responses mediated by CRSBP-1-PDGFR and by free PDGFR appear to be different, as evidenced by the observation that PDGF-BB (without a putative CRS motif) is much weaker than other CRSBP-1 ligands (PDGF peptide, VEGF peptide and VEGF-A165) in stimulating permeability in LEC monolayers and interstitiallymphatic transit in mice. Apparently, alterations in the morphology (distended lumens) and function (constitutively increased interstitial lymphatic-transit) of lymphatic capillary vessels cannot be compensated for, or rescued by, the presence of PDGFR and PDGF-BB in Crsbp1 -/-mice. Similarly to other CRSBP-1 ligands, PDGF-BB (Abcam ab73229), which a proteolytic product of PDGF-BB lacking a typical CRS motif, is unable to effectively stimulate interstitial-lymphatic transit in Crsbp1 -/-mice as determined by high molecular weight FITC-dextran mouse tail assay (Huang et al., 2006) . This suggests that PDGF-BB, which lacks a typical CRS motif, stimulates interstitial-lymphatic transit through interaction with PDGFR in the CRSBP-1-PDGFR complex in wild-type mice.
Materials and Methods
Materials
Na[
125 I] (17 Ci/mg) was obtained from ICN Biochemicals (Irvine, CA). PDGF peptide (a 19-mer peptide containing the amino acid sequence of YVRVRRPPKGKHRKFKHTH), VEGF peptide (a 25-mer peptide containing the amino acid sequence of KKSVRGKGKGQKRKRKKSRYKSWSV) and scrambled VEGF peptide (a 25-mer peptide which contained the same amino acid composition of VEGF peptide but with a scrambled amino acid sequence: KSKVKVRSKSKGKWKGRSKYRGKQR) were synthesized by C. S. Bio Co. (Menlo Park, CA). PDGF-BB, which lacks the putative CRS motif, was obtained from Abcam (Cambridge, MA). VEGF-A165 was a gift from Daniel T. Connolly (Mosanto, St Louis, MO). FITC-dextran (molecular weights ~40,000 and 2,000,000), DMEM, -carrageenan, chloramine-T and other biochemical reagents were obtained from Sigma (St Louis, MO). PDGF-BB, anti-phosphotyrosine, anti-VE-cadherin, anti--catenin, anti-p120-catenin, anti-VE-cadherin PY658, anti-VEcadherin PY731 and anti--catenin PY142 antibodies were obtained from Abcam. H1299/CRSBP-1 and H1299/vector cells were prepared as described (Huang et al., 2003) . SVEC4-10 cells and human dermal LECs (HDLECs) were obtained from American Type Culture Collection (Manassas, VA) and PromoCell (Heidelberg, Germany), respectively. Wild-type mice (C57/BL/6) were obtained from the Jackson Laboratory (Bar Harbor, ME). Crsbp1 -/-mice were generated as described previously (Huang et al., 2006) . Crsbp1 -/-mice have been included in the Induced Mutant Resources at the Jackson Laboratory, Bar Harbor, ME 04609 (Stock #006221,B6. 129Sl-XlkdlAEtmJhuaae/J). All experiments on live animals were performed in accordance with guidelines and regulations from the IACUC Office at St Louis University.
1242 Journal of Cell Science 124 (8) Fig. 7 . A model for CRSBP-1 regulation in VE-cadherin-mediated intercellular adhesion in LECs. At the cell surface, disulfide-linked homodimeric CRSBP-1 forms complexes with monomeric PDGFR and -catenin. Upon CRSBP-1 ligand binding, CRSBP-1 is induced to form oligomers or have a conformational change, resulting in the formation of dimers or oligomers of PDGFR. The PDGFR becomes activated and undergoes tyrosine autophosphorylation. Activation of PDGFR or activated PDGFR-mediated signaling cascades lead to increased tyrosine phosphorylation of VE-cadherin at Tyr658 and Tyr731 and -catenin at Tyr142, resulting in dissociation of -catenin and p120-catenin from VEcadherin (which trans dimerizes between cells) and subsequent internalization of VE-cadherin. -Catenin becomes dissociated from -catenin, leading to uncoupling of VE-cadherin junctions from actin cytoskeleton, disruption of VEcadherin-mediated intercellular adhesion and opening of intercellular junctions in LECs and increased interstitial-lymphatic transit in intact mice. Under the conditions of CRSBP-1 downregulation or null mutation, VE-cadherin-mediated intercellular adhesion (VE-cadherin transdimerization) is compromised.
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Immunofluorescence Cells grown on coverslips for 2 days (~50% confluency) were treated with CRSBP-1 ligands (10 M PDGF peptide, 10 M VEGF peptide, 0.2 M VEGF-A and 120 g/ml HA) or vehicle only for 30 minutes or 1 hour in serum-free DMEM. After treatment, cells were first washed with PBS twice, then fixed in 100% methanol at -20°C for 10 minutes. Following a rinse with PBS, cells were quenched in 0.1% sodium borohydride in PBS for 5 minutes. Cells were washed with PBS and blocked with 0.2% gelatin in PBS at room temperature for 1 hour. Cells were incubated for 1 hour with a 1:200 or 1:500 dilution of anti-CRSBP-1 antiserum, anti-VE-cadherin antibody, anti--catenin antibody, anti-VE-cadherin PY658 antibody, anti-VEcadherin PY731 antibody, or anti--catenin PY142 antibody in a solution of 0.2% gelatin in PBS followed by incubation with an 1:200 dilution of fluorescence-labeled secondary antibodies in a solution of 0.2% gelatin in PBS for 1 hours. Coverslips were then mounted on glass slides. The slides were viewed under an Olympus AHBT3 fluorescence microscope using interference green filters.
For immunofluorescence confocal microscopy of VE-cadherin--catenin intercellular junctions, SVEC4-10 cells and HDLECs were treated with CRSBP-1 ligands and fixed as described above. To estimate colocalization of VE-cadherin and -catenin in SVEC4-10 cells, confluent cells grown on coverslips were treated with CRSBP-1 ligands. Following fixation and blocking, cells were incubated overnight with anti-VE-cadherin antibody and anti--catenin antibody at 1:200 dilution. After extensive washing, cells were incubated with Rhodamine-Red-conjugated donkey anti-goat IgG antibody and FITC-conjugated mouse anti-rabbit antibody at 1:200 dilution for 1 hours. Images were acquired using a Leica TCS SP confocal microscope (Leica, Heidelberg, Germany).
siRNA transfection
Transfection of cells with Crsbp1 siRNA and control siRNA was performed according to the manufacturer's protocol (Santa Cruz Biotechnology). Briefly, SVEC4-10 cells were grown on P-60 dishes to 60-70% confluence. Cells were then washed twice with serum-free DMEM and 1.8 ml of transfection medium (sc-36868) was added to the cells. A 0.2 ml aliquot of transfection medium containing 0.15 nmoles Crsbp1 siRNA (sc-42902) or control siRNA (sc-37007) and 15 l of transfection reagent (sc-29528) was incubated at room temperature for 30 minutes before adding to the cells. The transfected cells were incubated at 37°C overnight. Following incubation, transfected cells were trypsinized and plated for experiments. Cells were used for experiments 48 hours after transfection.
Transwell permeability assay
SVEC4-10 cells transfected with Crsbp1 siRNA or control siRNA at 1.25ϫ10 5 cells or HDLEC at 1.5ϫ10 5 were grown on Transwell permeable supports (Corning, pore size 3.0 m, membrane diameter 6.5 mm, collagen coated) overnight. Inserts were washed once with serum-free DMEM and the lower chamber was filled with 0.6 ml of DMEM. Then 0.1 ml of vehicle, PDGF peptide (10 M) or VEGF peptide (10 M) in serum-free DMEM along with FITC-dextran 1 mg/ml (average MW ~40,000) was added to the top chamber. At several time points after FITC-dextran administration, a 50 l aliquot of DMEM was taken from the lower chamber. The amount of FITC-dextran diffused to the bottom chamber was determined and expressed as arbitrary units (AU).
Internalization of cell-surface VE-cadherin
SVEC4-10 cells grown in six-well plates were treated with vehicle only, 10 M PDGF peptide or 10 M VEGF peptide at 37°C for 30 minutes. Following treatment, cells were untreated or treated with trypsin as previously described (Boensch et al., 1999) to remove cell-surface proteins. Trypsin-undigested and trypsin-digested cells were subsequently lysed and subjected to reducing SDS-PAGE and electro-transferred onto PVDF membranes. Internalized or intracellular VE-cadherin, which was resistant to trypsin digestion, on PVDF membranes was visualized using streptavidin-HRP and the ECL system.
Tyrosine phosphorylation measurements
SVEC4-10 cells were grown on six-well plates until confluent. After washing with serum-free DMEM, cells were incubated with CRSBP-1 ligands (10 M PDGF peptide, 10 M VEGF peptide and 0.2 M VEGF-A165) for 30 minutes in serumfree DMEM. Cells were then lysed with 500 l of 1% Triton X-100 lysis buffer (50 mM Tris-HCl, 1 mM EDTA, 1 mM EGTA, 0.5 mM Na 3 VO 4 , 10 mM -glycerophosphate, 50 mM NaF, 5 mM sodium pyrophosphate). The Triton X-100 extracts were incubated with 5 l rabbit anti-PDGFR serum at 4°C overnight. A 50 l aliquot of agarose-protein-G gel (50% gel suspension) was then rotated with Triton X-100 extracts at 4°C. After 1 hour, the gel was washed three times with lysis buffer and eluted with 35 l SDS sample buffer. The eluted solution was subjected to reducing 7.5% SDS-PAGE. The separated proteins on SDS gels were electrotransferred onto PVDF membranes followed by western blot analysis using anti-phosphotyrosine antibody (Santa Cruz sc-7020). The membranes were also blotted using anti-VE-cadherin and anti--catenin antibodies as loading controls. The antigens on the blots were visualized by using horseradish-peroxidase-conjugated anti-mouse IgG antibody and the ECL system. The relative intensities of antigen bands on X-ray films were quantified by densitometry. For determination of tyrosine phosphorylation of VE-cadherin and -catenin, cell lysates of cells treated with CRSBP-1 ligands were subjected to SDS-PAGE, followed by quantitative western blot analysis using anti-VE-cadherin PY658, anti-VE-cadherin PY731 and anti--catenin PY142 antibodies (Santa Cruz Biotechnology). The PVDF membranes were also blotted using anti-VE-cadherin and anti--catenin antibodies as loading controls.
Co-immunoprecipitation
Confluent cells were collected and lysed with 1% Triton X-100 lysis buffer. The Triton X-100 extracts were incubated with 5 l rabbit anti-CRSBP-1 serum, nonimmune serum and anti-PDGFR serum at 4°C overnight. Fifty l of agaroseprotein-G gel (50% gel suspension) was then rotated with Triton X-100 extracts at 4°C for 1 hour. The agarose-protein-G gel was then washed three times with lysis buffer and eluted with 35 l SDS sample buffer. The eluted solution was subjected to reducing 7.5% SDS-PAGE. The separated proteins on SDS gels were electrotransferred onto PVDF membranes followed by western blot analysis using rabbit anti-PDGFR serum, anti--catenin antibody and p120-catenin. The antigens on the blots were visualized using horseradish-peroxidase-conjugated anti-rabbit IgG antibody and the ECL system.
FITC-dextran tail injection assay
The FITC-dextran tail injection assay was carried out as described (Huang et al., 2006) . To determine the interstitial-lymphatic transit in mice (five female mice per experimental group), 20 l of 8 mg/ml fluorescein isothiocyanate (FITC)-dextran (average MW ~2,000,000; Sigma) with and without PDGF-BB (0.25 g/20 l) or PDGF peptide (1 g/20 l) in phosphate-buffered saline (PBS) was injected intradermally into the tails of mice. The progressive diffusion (in the absence of injection pressure) of FITC-dextran fluorescence near the injection site was monitored over time with a UV lamp and a camera by fluorescence stereomicroscopy. The fluorescence intensity was determined using the NIH Image J program following photography. The relative fluorescence intensity in mice injected with PBS was taken as 100% (control). The interstitial-lymphatic transit analysis appeared to be quantitative and specific, as previously reported (Huang et al., 2006) .
-Carrageenan-induced edema in mouse paw
Wild-type and Crsbp1 -/-mice around 5-6 weeks old were separated into experimental groups. Each group of animals received subplantar injection without anesthesia of 25 l of -carrageenan (1% w/v in H 2 O) with and without 1.5 g VEGF peptide or PDGF peptide into footpads. The use of anesthetics to facilitate the handling of animals has been shown to inhibit the induction of paw swelling (Otterness and Moore, 1988) . Paw thickness was measured by using calipers (Mitutoyo, Japan) immediately before the subplantar injection and 1, 2, 3, 4, 5 hours afterward. The increase in paw thickness was determined as the difference between the paw thickness at each time point and the basal paw thickness. After experiments, animals were killed. The paws were fixed in formalin, and paraffin block sections were stained with hematoxylin and eosin (H&E) to examine paw edema and cellularity.
Statistical analysis
The values are presented as means ± s.d. (n4). Two-tailed unpaired Student's t-test was used to determine the significance of differences between groups. P<0.05 was considered significant. The data shown are representative of three to four independent experiments.
